Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy
Decline in respiratory function in patients with DMD starts during early teenage years and leads to early morbidity and mortality. Published evidence of efficacy for idebenone on respiratory function outcomes is currently limited to 12 months of follow-up time. Here we report data collected as retro...
Үндсэн зохиолчид: | Servais, L, Straathof, CSM, Schara, U, Klein, A, Leinonen, M, Hasham, S, Meier, T, De Waele, L, Gordish-Dressman, H, McDonald, CM, Mayer, OH, Voit, T, Mercuri, E, Buyse, GM |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
Elsevier
2019
|
Ижил төстэй зүйлс
-
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
-н: Theodora Markati, зэрэг
Хэвлэсэн: (2021-11-01) -
Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
-н: Marshall W. Hogarth, зэрэг
Хэвлэсэн: (2017-01-01) -
Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy
-н: Fatima Amor, зэрэг
Хэвлэсэн: (2021-06-01) -
Genetic modifiers of respiratory function in Duchenne muscular dystrophy
-н: Luca Bello, зэрэг
Хэвлэсэн: (2020-05-01) -
Duchenne Muscular Dystrophy
-н: J Gordon Millichap
Хэвлэсэн: (1989-05-01)